The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Costs and benefits of an organized fecal immunochemical test-based colorectal cancer screening program in the United States
Article first published online: 15 APR 2014
© 2014 American Cancer Society
Volume 120, Issue 15, pages 2308–2315, August 1, 2014
How to Cite
Guy, G. P., Richardson, L. C., Pignone, M. P. and Plescia, M. (2014), Costs and benefits of an organized fecal immunochemical test-based colorectal cancer screening program in the United States. Cancer, 120: 2308–2315. doi: 10.1002/cncr.28724
- Issue published online: 21 JUL 2014
- Article first published online: 15 APR 2014
- Manuscript Accepted: 11 MAR 2014
- Manuscript Revised: 25 FEB 2014
- Manuscript Received: 11 DEC 2013
- 1US Cancer Statistics Working Group. United States Cancer Statistics: 1999-2010 Incidence and Mortality Web-based Report. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2013. www.cdc.gov/uscs. Accessed February 25, 2014.
- 3The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity–United States, 2000 to 2006. J Am Acad Dermatol. 2011;65(5 suppl 1):S133-S143., , , , , .
- 4US Preventive Services Task Force. Screening for Colorectal Cancer. Rockville, MD: Agency for Healthcare Research and Quality; 2008. uspreventiveservicestaskforce.org/uspstf/uspscolo.htm. Accessed March 2, 2013.
- 7nccrt.org/about/policy-action/savings-to-medicare/. Accessed March 2, 2013., , . Methodology for Estimating the Potential Cost Savings to Medicare from Increased Colorectal Cancer Screening of the Pre-Medicare Population.
- 9Centers for Disease Control and Prevention (CDC). Cancer screening—United States, 2010. MMWR Morb Mortal Wkly Rep. 2012;61:41-45.
- 10US Department of Health and Human Services. Healthy People 2020. healthypeople.gov/2020/topicsobjectives2020/default.aspx. Accessed March 12, 2013.
- 14Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial. JAMA Intern Med. 2013;173:1725-1732., , , et al.
- 16US Census Bureau. Single Years of Age and Sex: 2010. factfinder2. census.gov/faces/tableservices/jsf/pages/productview.xhtml?pid=DEC_10_SF1_QTP2&prodType=table. Accessed March 12, 2013.
- 24Centers for Medicare and Medicaid Services. Physician Fee Schedule Search HCPCS Code 11400-11646. cms.gov/apps/physician-fee-schedule/search/search-results.aspx?Y=0&T=0&HT=2&CT=0&H1-11400&H2=11646&M=5. Accessed April 10, 2013.
- 25Cost-effectiveness of colonoscopy. Gastrointest Endosc Clin N Am. 2010;20:751-770..
- 30A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int J Cancer. 2011;128:2415-2424., , , et al.
- 32Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia. Med J Aust. 2011;194:180-185., , , , , .